The brain tumor microenvironment (TME) is emerging as a critical regulator of cancer
progression in primary and metastatic brain malignancies. The unique properties of this …

Despite recent progress in understanding the cancer genome, there is still a relative delay in
understanding the full aspects of the glycome and glycoproteome of cancer. Glycobiology …

Increased overall survival for patients with glioma brain tumours is associated with mutations
in the metabolic regulator isocitrate dehydrogenase 1 (IDH1). Gliomas develop within a …

Sulfation is a dynamic and complex posttranslational modification process. It can occur at
various positions within the glycosaminoglycan (GAG) backbone and modulates …

Glioblastoma is the most common primary malignant brain tumour. Survival is poor and
improved treatment options are urgently needed. Although immunotherapies have emerged …

An outstanding characteristic of gliomas is their infiltration into brain parenchyma, a property
that impairs complete surgical resection; consequently, these tumors might recur, resulting in …

Glioblastoma multiforme (GBMs) are recurrent lethal brain tumours. Recurrent GBMs often
exhibit mesenchymal, stem-like phenotypes that could explain their resistance to therapy …

Stem and progenitor cells are characterized by their ability to self-renew and produce
differentiated progeny. A fine balance between these processes is achieved through …

Glioblastoma (GBM) is the most common and malignant form of primary brain tumor with a
median survival time of 14–16 months in GBM patients. Surgical treatment with …

The heterogeneous expression of tumor-associated antigens limits the efficacy of chimeric
antigen receptor (CAR)–redirected T cells (CAR-Ts) for the treatment of glioblastoma (GBM) …